REGULAR CONTENT
Final ID
660
Type
Educational Exhibit-Poster Only
Authors
R Gnanasekaran1, G O'Sullivan2
Institutions
1John Radcliffe Hospital, Oxford, United Kingdom, 2University College Hospital, Galway, Ireland
Purpose
To report our initial experience with the use of a new implantable, self-expanding vascular plug.
Materials & Methods
Vascular plugs are permanent mechanical embolic devices that activate the clotting cascade leading to vessel thrombosis. The most popular plug is the Amplatzer Vascular Plug (AVP) which consists of a self-expanding nitinol mesh with a detachable deployment wire 1,2. However, a major issue with the AVP is the prolonged occlusion time and this is problematic in the embolization of high flow, large diameter vessels or in coagulopathic patients2,3. The following report details our experience with the EMBA™ Hourglass™ peripheral embolization device. In contrast to the AVP, the Hourglass™ is designed to immediately obstruct or reduce blood flow in vessels sized 3-8mm in diameter.
Results
The device consists of a self-expanding vascular plug in a preloaded catheter based system. The embolic implant is delivered on a tri-axial catheter based system containing a guidewire, pusher and outer body which provides integrated contrast injection capability. A guidewire is inserted through a 0.018-0.035' selective catheter to the target. The catheter is removed and the device is advanced over the guidewire until the device and delivery system are in the desired location. The position and stability of the device is then checked under fluoroscopy by injecting contrast through the integrated delivery system before the device is deployed. Once the Hourglass™ has been deployed, the occlusion can be verified by injecting contrast through the delivery system. The embolic implant device is an hour glass shape with a covering on the proximal 50% and this covering is used to occlude the vessel. The shape and covering allows the rapid occlusion of the target vessel and stable placement of the device.
Conclusions
In our experience, the main advantages of the Hourglass™ are the rapid occlusion time, stability in the target vessel and precise delivery. This has several benefits including shorter operating times and a smaller likelihood of requiring other embolic agents such as coils due to an incomplete occlusion.
Final ID
660
Type
Educational Exhibit-Poster Only
Authors
R Gnanasekaran1, G O'Sullivan2
Institutions
1John Radcliffe Hospital, Oxford, United Kingdom, 2University College Hospital, Galway, Ireland
Purpose
To report our initial experience with the use of a new implantable, self-expanding vascular plug.
Materials & Methods
Vascular plugs are permanent mechanical embolic devices that activate the clotting cascade leading to vessel thrombosis. The most popular plug is the Amplatzer Vascular Plug (AVP) which consists of a self-expanding nitinol mesh with a detachable deployment wire 1,2. However, a major issue with the AVP is the prolonged occlusion time and this is problematic in the embolization of high flow, large diameter vessels or in coagulopathic patients2,3. The following report details our experience with the EMBA™ Hourglass™ peripheral embolization device. In contrast to the AVP, the Hourglass™ is designed to immediately obstruct or reduce blood flow in vessels sized 3-8mm in diameter.
Results
The device consists of a self-expanding vascular plug in a preloaded catheter based system. The embolic implant is delivered on a tri-axial catheter based system containing a guidewire, pusher and outer body which provides integrated contrast injection capability. A guidewire is inserted through a 0.018-0.035' selective catheter to the target. The catheter is removed and the device is advanced over the guidewire until the device and delivery system are in the desired location. The position and stability of the device is then checked under fluoroscopy by injecting contrast through the integrated delivery system before the device is deployed. Once the Hourglass™ has been deployed, the occlusion can be verified by injecting contrast through the delivery system. The embolic implant device is an hour glass shape with a covering on the proximal 50% and this covering is used to occlude the vessel. The shape and covering allows the rapid occlusion of the target vessel and stable placement of the device.
Conclusions
In our experience, the main advantages of the Hourglass™ are the rapid occlusion time, stability in the target vessel and precise delivery. This has several benefits including shorter operating times and a smaller likelihood of requiring other embolic agents such as coils due to an incomplete occlusion.